These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma. Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014 [TBL] [Abstract][Full Text] [Related]
4. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma. Nguyen TH; Barr FG Molecules; 2018 Oct; 23(11):. PubMed ID: 30373318 [TBL] [Abstract][Full Text] [Related]
6. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma. Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669 [TBL] [Abstract][Full Text] [Related]
7. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416 [TBL] [Abstract][Full Text] [Related]
8. Uncovering metabolism in rhabdomyosarcoma. Monti E; Fanzani A Cell Cycle; 2016; 15(2):184-95. PubMed ID: 26209235 [TBL] [Abstract][Full Text] [Related]
9. Update on molecular findings in rhabdomyosarcoma. El Demellawy D; McGowan-Jordan J; de Nanassy J; Chernetsova E; Nasr A Pathology; 2017 Apr; 49(3):238-246. PubMed ID: 28256213 [TBL] [Abstract][Full Text] [Related]
10. Signaling pathways in Rhabdomyosarcoma invasion and metastasis. Ramadan F; Fahs A; Ghayad SE; Saab R Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508 [TBL] [Abstract][Full Text] [Related]
11. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889 [TBL] [Abstract][Full Text] [Related]
12. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413 [TBL] [Abstract][Full Text] [Related]
13. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors. de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386 [TBL] [Abstract][Full Text] [Related]
14. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target. Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519 [TBL] [Abstract][Full Text] [Related]
15. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
16. Molecular diagnostics in the management of rhabdomyosarcoma. Arnold MA; Barr FG Expert Rev Mol Diagn; 2017 Feb; 17(2):189-194. PubMed ID: 28058850 [TBL] [Abstract][Full Text] [Related]
17. The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth. Gualtieri A; Bianconi V; Renzini A; Pieroni L; Licursi V; Mozzetta C Cell Rep; 2022 Aug; 40(9):111267. PubMed ID: 36044855 [TBL] [Abstract][Full Text] [Related]
19. Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation. Perrone C; Pomella S; Cassandri M; Pezzella M; Giuliani S; Gasperi T; Porrazzo A; Alisi A; Pastore A; Codenotti S; Fanzani A; Barillari G; Conti LA; De Angelis B; Quintarelli C; Mariottini P; Locatelli F; Marampon F; Rota R; Cervelli M Front Cell Dev Biol; 2023; 11():1061570. PubMed ID: 36755974 [TBL] [Abstract][Full Text] [Related]
20. Rhabdomyosarcomas are oncogene addicted to the activation of AVIL. Xie Z; Janczyk PL; Shi X; Wang Q; Singh S; Cornelison R; Xu J; Mandell JW; Barr FG; Li H Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2118048119. PubMed ID: 37146302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]